Oral-ATO for TP53-mutated Myeloid Malignancies

This study is testing oral arsenic trioxide combined with other drugs as a treatment for blood cancers — specifically acute myeloid leukemia (AML), a type of bone marrow cancer called myelodysplastic syndrome (MDS), or chronic myelomonocytic leukemia (CMML) — that have a specific mutation in the TP53 gene. This mutation makes these cancers particularly hard to treat. **You may be eligible if...** - You are 18 years of age or older - You have been diagnosed with AML, MDS, or CMML with a confirmed TP53 mutation - You are either newly diagnosed (Cohort A) or have already received at least one prior treatment that did not work (Cohort B) - You are able to perform basic daily activities (ECOG performance status 0–2) - You are willing to use effective contraception during treatment **You may NOT be eligible if...** - You have certain heart problems (such as prolonged QT interval) - You have severe liver or kidney problems - You are pregnant or breastfeeding - You have active, uncontrolled infection Talk to your doctor to see if this trial is right for you.